Conference Coverage

Migraine treatment insights offered for noninvasive vagus nerve stimulation


 

EXPERT ANALYSIS FROM THE AHS ANNUAL MEETING

Using the nVNS device

This nVNS device produces a proprietary, low-voltage electrical signal with a 24-volt peak voltage and a 60-mA peak output current. In the PRESTO study, patients were instructed to self-administer bilateral 120-second stimulations to the right and left sides of their necks within 20 minutes of pain onset. If the pain hadn’t improved within 15 minutes, they were to repeat the stimulations.

In a post hoc analysis of the PREVA (Prevention and Acute treatment of chronic cluster headache) study (Cephalalgia. 2016;36[6]:534-46), investigators determined that the mean reduction in the number of cluster headache attacks was significantly greater in patients who used the device to treat at least 77% of their attacks. That had a bigger preventive effect than did the number of stimulations a patient applied per day.

The PRESTO and PREVA trials were sponsored by electroCore, where Mr. Liebler is employed.

Pages

Recommended Reading

Most U.S. buprenorphine prescribers assess patients for diversion
MDedge Neurology
Mobile app engages individuals with opioid use disorders
MDedge Neurology
Trump support high in counties with chronic opioid use
MDedge Neurology
T1D neuropathy declines as glycemic control improves
MDedge Neurology
Methamphetamine use climbing among opioid users
MDedge Neurology
Migraine and menopause: Longitudinal study shows what to expect
MDedge Neurology
Study busts three migraine trigger myths
MDedge Neurology
OnabotulinumtoxinA crushes topiramate in chronic migraine PRO benefits
MDedge Neurology
Device impresses for chronic cluster headache attacks
MDedge Neurology
Fentanyl analogs nearly double their overdose death toll
MDedge Neurology